Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1623 1626 1627 1629 1636
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18252611 | MAGL INHIBITORS | Final Rejection | H. LUNDBECK A/S |
| 18970142 | Imidazole Compounds for Organic Light-Emitting Diodes | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18033662 | PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE | Final Rejection | Vanderbilt University |
| 18832840 | HETEROCYCLIC COMPOUNDS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18249435 | INHIBITION OF THE HIV-1 REPLICATION BY COMPOUNDS DIRECTED AGAINST A NEW TARGET OF THE VIRAL CYCLE | Final Rejection | UNIVERSITE PARIS-SACLAY |
| 18848394 | ENPP1 INHIBITOR | Non-Final OA | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. |
| 18248858 | HETEROCYCLIC GLP-1 AGONISTS | Non-Final OA | Gasherbrum Bio, Inc. |
| 17788378 | Aqueous Composition | Final Rejection | Rohto Pharmaceutical Co., Ltd. |
| 18579826 | NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE | Non-Final OA | MSN LABORATORIES PRIVATE LTD, R&D CENTER |
| 18562510 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | Non-Final OA | Disc Medicine, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy